Pharmacologic management of obesity

Primary Care Update for Ob/Gyns

Volumn 5, Issue 2, 1998, Pages 101-107

  Tsai, Lynette W ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; AMPHETAMINE; ANOREXIGENIC AGENT; BENZPHETAMINE; DEXAMPHETAMINE; DEXFENFLURAMINE; FENFLURAMINE; MAZINDOL; PHENDIMETRAZINE; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PHENTERMINE RESIN; PHENYLPROPANOLAMINE; PRELU 2; UNCLASSIFIED DRUG;

BODY MASS; DIET RESTRICTION; DRUG MECHANISM; EXERCISE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; NEUROLOGIC DISEASE; OBESITY; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; TACHYCARDIA; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

EID: 0032030443     PISSN: 1068607X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1068-607X(98)00003-1     Document Type: Article

References (20)

1. 1. Williamson DF. Descriptive epidemiology of body weight and weight change in U.S. adults. Ann Intern Med 1993;119:646-9.
2. 2. Maddox GL, Anderson CF, Bogdonoff MD. Am J Med Sci 1966;252: 394.
3. 3. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993;119: 655-60.
4. 4. Kannel WB, Brand N, Skinner JJ Jr, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension: The Framingham Study. Ann Intern Med 1967;67:48-59.
5. 5. Bouchard C. Genetic factors in obesity. Med Clin North Am 1989;73: 67-81.
6. 6. Goldstein D, Potvin J. Long term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994; 60:647-57.
7. 7. Vener A, Krupka L, Gerard R. Overweight/obese patients: an overview. Practitioner 1982;226:1102-9.
8. 8. Goldstein D. Beneficial health effects of modest weight loss. Int J Obesity 1992;16:397-415.
9. 9. Conolly HM, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
10. 10. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993; 119:707-13.
11. 11. Wellman P. Overview of adrenergic anorectic agents. Am J Clin Nutr 1992;55:193S-8S.
12. 12. Enzi G, Baritussio A, Marchiori E, Crepaldi G. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity. J Int Med Res 1976;4:305-18.
13. 13. Kumahara Y, Kumagai A, Goto Y, Shizume K, Naito C, Onishi T. Clinical evaluation of mazindol, an anorexiant, on obesity-multicenter double blind study in comparison with placebo. Clin Eval 1985;13: 461-514.
14. 14. Tauber-Lassen E, Damsbo P, Henriksen JE, Palmvig B, Beck-Nielsen H. Improvement of glycemic control and weight loss in type 2 (non-insulin dependent) diabetics after one year of dexfenfluramine treatment. Diabetologia 1990;33 suppl: A124.
15. 15. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335: 609-16.
16. 16. Abenhaim L, et al. The international primary pulmonary hypertension study. Chest 1994;105 Suppl 2:37S-41S.
17. 17. Gardin JM, Wagenknecht LE, Anton-Culver H, Flack J, Gidding S, Kurosaki T, Wong ND, Manolio TA. CARDIA study, Coronary Artery Risk Development in Young Adult. Circulation 1995;92:P.380-7.
18. 18. U.S. Food and Drug Administration home page: http//www. fda.gov. U.S. FDA.
19. 19. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH, A double-blind clinical trial in weight control. Arch Intern Med 1984;144:1143-8.
20. 20. Weintraub M, et al. Long-term weight control: the National Heart, Lung, and Blood Institute funded mulitomodal intervention study. Parts I-VII and conclusions. Clin Pharmacol Ther 1992;51:584-646.